Investigation of the Effect of Oral Powder Enriched with Curcumin and Probiotics on Cardiometabolic Indices of Patients with Metabolic Syndrome

Phase 3

Recruiting

• Conditions: Metabolic Syndrome.; Metabolic syndrome; E88.81

• Registration Number: IRCT20220315054290N2
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 124

Inclusion Criteria

Age: 30-60 years old
Metabolic syndrome patients are diagnosed based on the Adult Treatment Panel III (ATP III) criterion
Consent to participate in the study

Exclusion Criteria

Pregnancy
Lactation
Metabolic, endocrine, and cardiovascular diseases except diabetes, dyslipidemia, and hypertension

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Castelli Risk Index I. Timepoint: Before the study and 8 weeks after the start of the study. Method of measurement: Castelli risk index I = TC/HDL - C.;Castelli Risk Index II. Timepoint: Before the study and 8 weeks after the start of the study. Method of measurement: Castelli risk index II = LDL - C/HDL - C.;Atherogenic Index of Plasma (AIP). Timepoint: Before the study and 8 weeks after the start of the study. Method of measurement: AIP = log (TG/HDL - C).;Atherogenic Coefficient = AC. Timepoint: Before the study and 8 weeks after the start of the study. Method of measurement: AC = (TC - HDL - C)/HDL - C.